BioRender 图标

Neuroblastoma (SH-SY5Y, apoptosis, blebbing)

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) - Editable icon of A differentiated SH-SY5Y neuroblastoma with a budding axon and a pyramidal body, blebbing and undergoing apoptosis
[{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68f0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68f0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ef/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ef/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ee/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ee/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ed/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ed/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ec/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ec/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68eb/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68eb/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ea/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ea/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68e0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68e0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68df/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68df/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68de/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68de/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68dd/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68dd/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68dc/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68dc/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68db/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68db/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68da/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68da/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d5/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d4/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d4/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d3/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d3/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d2/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d2/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d1/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d1/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68d0/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68d0/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cf/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cf/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ce/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ce/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cd/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cd/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cc/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cc/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68cb/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68cb/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68ca/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68ca/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c9/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c9/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c8/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c8/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c7/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c7/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c6/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c6/630633e17c75bb00281a685f.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630635527c75bb00281a68c5/630633e17c75bb00281a685f.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630635527c75bb00281a68c5/630633e17c75bb00281a685f.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
neuroblastoma,apoptosis,blebbing,cell death,programmed cell death,nuclear fragmentation,necrosis,capsase,protease,degradation,atrophy,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,SH-sy5y
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon JPEG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon PNG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon SVG

Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon GIF

BioRender 图标常见问题解答

How are scientists using the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, apoptosis, blebbing) icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon